Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 5/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668974 | 1.00 | MAPT (0.57) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL2223617 | 0.86 | MAPT (0.47) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL12442318 | 0.86 | MAPT (0.47) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL11126772 | 0.85 | MAPT (0.43) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL11883815 | 0.84 | MAPT (0.44) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL11883801 | 0.84 | MAPT (0.44) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL11883796 | 0.84 | MAPT (0.44) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL10277707 | 0.83 | ALDH1A1 (0.42) | MAPTALDH1A1SMN1; SMN2ICMT | |
| SCHEMBL16745722 | 0.83 | MAPT (0.59) | MAPTALDH1A1KDM4ETHRBALOX15 | |
| SCHEMBL6308419 | 0.83 | MAPT (0.59) | MAPTALDH1A1KDM4ETHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239111-B1 | DRUG FOR TREATING BRAIN DISEASES, ENABLES PREVENTION OR TREATMENT OF DEMENTIA AND SIMILAR DISEASES CAUSED BY DEGENERATION OR SLOUGHING OF NEURONS, AN ALLY SULFIDE, SULFOXIDE OR SULFONE | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | claimed |
| EP-0051682-B1 | CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1984-09-05 | — | — | EP | claimed |
| EP-0051682-A1 | CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-19 | — | — | EP | claimed |
| US-20240257973-A1 | DISEASE SPECTRUM CLASSIFICATION | PATIENTSLIKEME LLC (US) | 2024-08-01 | — | — | US | disclosed |
| US-11894139-B1 | Disease spectrum classification | PATIENTSLIKEME LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20220102000-A1 | PREDICTING BLOOD METABOLITES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-03-31 | — | — | US | disclosed |
| CN-111960978-A | Synthesis method and application of S-allyl-L-cysteine substituted tyrosol derivative with neuroprotective activity | 深圳红景堂生物医药科技有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-10758498-B2 | Method of decreasing protein-aldehyde adducts by administering a mixed disulfide of n-acetylcysteine and propyl mercaptan, propenyl mercaptan, or allyl mercaptan | SOCTRONICS TECHNOLOGIES PRIVATE LIMITED (IN) | 2020-09-01 | — | — | US | disclosed |
| US-10258581-B2 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases | OTT DAVID MICHAEL (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190076377-A1 | ORGANOSULFUR COMPOUNDS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | SOCTRONICS TECHNOLOGIES PRIVATE LIMITED (IN) | 2019-03-14 | — | — | US | disclosed |
| US-10118891-B2 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases | Allium Vitalis, Inc. (US) | 2018-11-06 | — | — | US | disclosed |
| EP-1901701-A2 | PERSONAL CARE AND MEDICINAL PRODUCTS INCORPORATING BOUND ORGANOSULFUR GROUPS | Ott, David M. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006127918-A2 | PERSONAL CARE AND MEDICINAL PRODUCTS INCORPORATING BOUND ORGANOSULFUR GROUPS | OTT DAVID M (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060269488-A1 | Personal care and medicinal products incorporating bound organosulfur groups | ALLIUM VITALIS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| US-20050260250-A1 | Medicinal products incorporating bound organosulfur groups | ALLIUM VITALIS INCORPORATED | 2005-11-24 | — | — | US | disclosed |
| US-20040235946-A1 | Organosulphur prodrugs for the prevention and treatment of injectious diseases and pathologenic immune system response | ALLIUM VITALIS INCORPORATED | 2004-11-25 | — | — | US | disclosed |
| EP-0885608-A1 | REMEDIES FOR BRAIN DISEASES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0051682-B1 | CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1984-09-05 | — | — | EP | disclosed |
| US-4440788-A | REGENERATION OF LIVER CELLS | MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) | 1984-04-03 | — | — | US | disclosed |
| EP-0051682-A1 | CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076377-A1 | ORGANOSULFUR COMPOUNDS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PARK7, TST | MAPT 49/4885ALDH1A1 176/4885KDM4E 4177/4885 |
| US-20040235946-A1 | Organosulphur prodrugs for the prevention and treatment of injectious diseases and pathologenic immune system response | TST, AHCY, SHMT1 | MAPT 4189/4885ALDH1A1 2741/4885KDM4E 4556/4885 |
| US-10758498-B2 | Method of decreasing protein-aldehyde adducts by administering a mixed disulfide of n-acetylcysteine and propyl mercaptan, propenyl mercaptan, or allyl mercaptan | SNCA, PARK7, MGMT | MAPT 114/4885ALDH1A1 201/4885KDM4E 4516/4885 |
| US-10258581-B2 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases | SNCA, PARK7, TST | MAPT 49/4885ALDH1A1 176/4885KDM4E 4177/4885 |
| US-20050260250-A1 | Medicinal products incorporating bound organosulfur groups | CBS, TST, CTH | MAPT 2232/4885ALDH1A1 675/4885KDM4E 4483/4885 |
| US-20060269488-A1 | Personal care and medicinal products incorporating bound organosulfur groups | LPO, TST, SCLY | MAPT 2750/4885ALDH1A1 1461/4885KDM4E 2322/4885 |
| US-10118891-B2 | Organosulfur compounds for the prevention and treatment of neurodegenerative diseases | SNCA, PARK7, TARDBP | MAPT 30/4885ALDH1A1 213/4885KDM4E 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.